EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting TTK Inhibits Tumorigenesis of T‐Cell Lymphoma Through Dephosphorylating p38α and Activating AMPK/mTOR Pathway

Bingyu Liu, Tiange Lu, Mengfei Ding, Xiaoli Zhou, Yujie Jiang, Juanjuan Shang, Wenyue Sun, Shunfeng Hu, Xin Wang, Xiangxiang Zhou iD

Advanced Science · 2025-03 · 12 (10)

DOI: 10.1002/advs.202413990 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 21.01.2025. Verfasst von Bingyu Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250021, China. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Lymphoma, T-Cell, AMP-Activated Protein Kinases, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation, Taishan Scholars Program of Shandong Province, Translational Research Grant of NCRCH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T‐cell lymphoma (TCL) is a group of non‐Hodgkin's lymphoma with high heterogeneity and unfavorable prognosis. Current standard treatments have demonstrated limited efficacy in improving the outcomes for TCL patients. Therefore, identification of novel drug targets is urgently needed to improve the prognosis of TCL patients. Through multi‐omics analysis, aberrant expression of threonine tyrosine kinase (TTK) in TCL is identified. High expression of TTK is closely associated with poor prognosis in TCL patients. Targeting TTK through gene knockdown exerts anti‐tumor effects in vitro and in vivo, including inhibiting the cell proliferation, inducing G2/M phase arrest, enhancing DNA damage and cell apoptosis. Mechanically, p38α is identified as the potential phosphorylation substrate of TTK through phosphoproteomic quantification and motif prediction. Furthermore, inhibition of TTK suppresses activation of p38α through dephosphorylating it at Thr180/Tyr182, thereby promoting the activation of AMPK/mTOR pathway. In addition, targeting TTK enhances the autophagy in TCL cells through dephosphorylating p38α. CFI‐402257, a specific inhibitor of TTK, is found to exhibit anti‐tumor effects and exerted synergistic efficacy with PI3K inhibitor, Duvelisib, in TCL. The study shows that TTK contributes to the development of TCL by regulating p38α‐mediated AMPK/mTOR pathway. CFI‐402257 is expected to be a promising strategy for TCL treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TOR Serine-Threonine KinasesLymphoma, T-CellAMP-Activated Protein KinasesProtein Serine-Threonine KinasesMitogen-Activated Protein Kinase 14CarcinogenesisHumansMiceAnimalsSignal TransductionCell Line, TumorPhosphorylationCell ProliferationApoptosis

Stichwörter der Autor:innen

T‐cell lymphomap38αphosphorylationthreonine tyrosine kinaseubiquitination

Substanzen

TOR Serine-Threonine KinasesAMP-Activated Protein KinasesMTOR protein, humanProtein Serine-Threonine KinasesMitogen-Activated Protein Kinase 14

Autor:innen und Institutionen

  • Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250021, China.
  • Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.
  • Branch of National Clinical Research Center for Hematologic Diseases, Jinan, Shandong, 250021, China.

ORCID-Profile: Xiangxiang Zhou

Förderung

  • National Natural Science Foundation
  • Taishan Scholars Program of Shandong Province
  • Translational Research Grant of NCRCH
  • Academic Promotion Programme of Shandong First Medical University
  • China Postdoctoral Science Foundation
  • Shandong Provincial Natural Science Foundation
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Liu, B., Lu, T., Ding, M., Zhou, X., Jiang, Y., Shang, J., Sun, W., Hu, S., Wang, X., & Zhou, X. (2025). Targeting TTK Inhibits Tumorigenesis of T‐Cell Lymphoma Through Dephosphorylating p38α and Activating AMPK/mTOR Pathway. Advanced Science, 12(10). https://doi.org/10.1002/advs.202413990

Vancouver

Liu B, Lu T, Ding M, Zhou X, Jiang Y, Shang J, et al. Targeting TTK Inhibits Tumorigenesis of T‐Cell Lymphoma Through Dephosphorylating p38α and Activating AMPK/mTOR Pathway. Advanced Science. 2025;12(10). doi:10.1002/advs.202413990

BibTeX
@article{Liu2025,
  author = {Liu, Bingyu and Lu, Tiange and Ding, Mengfei and Zhou, Xiaoli and Jiang, Yujie and Shang, Juanjuan and Sun, Wenyue and Hu, Shunfeng and Wang, Xin and Zhou, Xiangxiang},
  title = {Targeting TTK Inhibits Tumorigenesis of T‐Cell Lymphoma Through Dephosphorylating p38α and Activating AMPK/mTOR Pathway},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {10},
  doi = {10.1002/advs.202413990}
}
Kostenlos starten →